Title:
BIOMARKER HGF FOR PREDICTING EFFICACY OF C-MET INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2018/080015
Kind Code:
A1
Abstract:
Provided are a biomarker HGF for predicting the efficacy of a c-Met inhibitor, and a composition for predicting the efficacy of a c-Met inhibitor, comprising a detection substance for an HGF, and/or for selecting a subject for the application of a c-Met inhibitor.
Inventors:
SHIM SEON HUI (KR)
KIM KYUNGAH (KR)
KIM BO GYOU (KR)
NAM DO-HYUN (KR)
KIM KYUNGAH (KR)
KIM BO GYOU (KR)
NAM DO-HYUN (KR)
Application Number:
PCT/KR2017/010093
Publication Date:
May 03, 2018
Filing Date:
September 14, 2017
Export Citation:
Assignee:
SAMSUNG ELECTRONICS CO LTD (KR)
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR)
SAMSUNG BIOEPIS CO LTD (KR)
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR)
SAMSUNG BIOEPIS CO LTD (KR)
International Classes:
C12Q1/68; G01N33/574
Domestic Patent References:
| WO2016054414A1 | 2016-04-07 |
Foreign References:
| KR20140002711A | 2014-01-08 | |||
| KR20130036993A | 2013-04-15 | |||
| KR20150082121A | 2015-07-15 |
Other References:
XIE, QIAN ET AL.: "Hepatocyte Growth Factor (HGF) Autocrine Activation Predicts Sensitivity to MET Inhibition in Glioblastoma", PNAS, vol. 109, no. 2, 10 January 2012 (2012-01-10), pages 570 - 575, XP055480557
Attorney, Agent or Firm:
PANKOREA PATENT AND LAW FIRM (KR)
Download PDF:
Previous Patent: CHAMBER DEVICE FOR EYEBALL AND RESPIRATORY TOXICITY EVALUATION FOR TEST MATERIAL
Next Patent: CURTAIN-TYPE VERTICAL BLIND
Next Patent: CURTAIN-TYPE VERTICAL BLIND